Login to Your Account



AAIC 2012

Going Upstream in Time and Path May Bring APP Success

By Anette Breindl
Science Editor

Monday, July 23, 2012

Anyone who thinks that the term "the dismal science" refers to economics is clearly not involved in clinical trials for Alzheimer's disease, an indication which has dashed the last 13 Phase III trials attempting to make a dent in it.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription